drugset / Trial / NCT03061539
Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective is to test the following hypothesis: Patients with metastatic castrate resistant prostate cancer that have progressed following at least one line of therapy and have an immunogenic signature will respond to combined PD-1 and CTLA4 inhibition.
Timeline
- Start
- 2018-02-06
- Primary completion
- 2022-06-20
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |